Literature DB >> 15306174

Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects.

Jason M R Gill1, Jacqueline C Brown, Dorothy Bedford, Dawn M Wright, Josephine Cooney, David A Hughes, Chris J Packard, Muriel J Caslake.   

Abstract

Insulin resistance is probably the defining feature of the metabolic syndrome and is an important determinant of plasma triglyceride (TG) concentrations. We sought to investigate whether insulin resistance influenced the metabolism of VLDL1 (Sf 60-400) and VLDL2 (Sf 20-60). Sixteen (eight men, eight women) middle-aged, normoglycaemic subjects participated. VLDL1and VLDL2 apolipoprotein (apo) B metabolism was followed using a deuterated leucine tracer and insulin resistance was estimated using homeostasis model assessment (HOMA). HOMA-estimated insulin resistance (HOMAIR) significantly and strongly correlated with the VLDL1 production rate (r = 0.69, P < 0.01) and VLDL1 apo B pool size (r = 0.59, P = 0.02), but these relationships were not evident for VLDL2. Conversely, HOMAIR was not significantly related to the fractional rate of transfer of VLDL1 to VLDL2 but was significantly related to the fractional rate of transfer from VLDL2 to IDL (r = 0.61, P = 0.01). HOMAIR was not significantly related to the fractional rate of direct catabolism for either VLDL1 or VLDL2. These results suggest a role for insulin resistance in the determination of hepatic VLDL1 production and highlight the independent regulation of VLDL1 and VLDL2 metabolism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15306174     DOI: 10.1016/j.atherosclerosis.2004.04.022

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  18 in total

1.  Impaired-inactivation of FoxO1 contributes to glucose-mediated increases in serum very low-density lipoprotein.

Authors:  Ke Wu; David Cappel; Melissa Martinez; John M Stafford
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

Review 2.  Hepatic ABCA1 and VLDL triglyceride production.

Authors:  Mingxia Liu; Soonkyu Chung; Gregory S Shelness; John S Parks
Journal:  Biochim Biophys Acta       Date:  2011-10-06

3.  Basal and insulin-regulated VLDL1 and VLDL2 kinetics in men with type 2 diabetes.

Authors:  Rakel F Johansen; Esben Søndergaard; Lars Peter Sørensen; Anne Grethe Jurik; Jens S Christiansen; Søren Nielsen
Journal:  Diabetologia       Date:  2016-01-19       Impact factor: 10.122

4.  Hepatic Fatty Acid Balance and Hepatic Fat Content in Humans With Severe Obesity.

Authors:  Kelli A Lytle; Nikki C Bush; Jessica M Triay; Todd A Kellogg; Michael L Kendrick; James M Swain; Nicola W Gathaiya; Kazanna C Hames; Michael D Jensen
Journal:  J Clin Endocrinol Metab       Date:  2019-12-01       Impact factor: 5.958

Review 5.  Chronic hepatitis C virus infection and lipoprotein metabolism.

Authors:  Yoshio Aizawa; Nobuyoshi Seki; Tomohisa Nagano; Hiroshi Abe
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

6.  Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.

Authors:  Hyohun Park; Toshihide Shima; Kanji Yamaguchi; Hironori Mitsuyoshi; Masahito Minami; Kohichiroh Yasui; Yoshito Itoh; Toshikazu Yoshikawa; Michiaki Fukui; Goji Hasegawa; Naoto Nakamura; Mitsuhiro Ohta; Hiroshi Obayashi; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2010-07-24       Impact factor: 7.527

7.  Is there a relation between triglyceride concentrations in very low density lipoprotein and the index of insulin resistance in nondiabetic subjects?

Authors:  Yoshifumi Kurosaki; Tomoaki Tsukushi; Shinichi Munekata; Yuhsaku Kanoh; Tatsumi Moriya; Makoto Nishinari; Naoyoshi Aoyama; Zensuke Ogawa
Journal:  J Clin Lab Anal       Date:  2014-02-27       Impact factor: 2.352

Review 8.  Fatty liver, insulin resistance, and dyslipidemia.

Authors:  Martin Adiels; Marja-Riitta Taskinen; Jan Borén
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

9.  Overproduction of large VLDL particles is driven by increased liver fat content in man.

Authors:  M Adiels; M-R Taskinen; C Packard; M J Caslake; A Soro-Paavonen; J Westerbacka; S Vehkavaara; A Häkkinen; S-O Olofsson; H Yki-Järvinen; J Borén
Journal:  Diabetologia       Date:  2006-02-04       Impact factor: 10.122

10.  Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III.

Authors:  Doris T Chan; Gursharan K Dogra; Ashley B Irish; Esther M Ooi; P Hugh Barrett; Dick C Chan; Gerald F Watts
Journal:  J Lipid Res       Date:  2009-06-21       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.